Vertex Pharmaceuticals (VRTX) reported its third quarter 2024 financial results, achieving a revenue of $2.77 billion, an 11.59% increase year-over-year, which exceeded expectations by $52 million. The company's earnings per share (EPS) stood at $4.38, marking a 7.35% year-over-year rise and beating estimates by $0.24. Bruker Corporation (BRKR) also announced its third quarter 2024 financial results, with shares trading down 5.6% in pre-market activity following the announcement. Verve Therapeutics (VERV) disclosed pipeline progress alongside its third quarter results, although specific financial figures were not detailed. Additional companies reporting their third quarter results included Treace Medical Concepts (TMCI), Cytek Biosciences (CTKB), Lantheus (LNTH), LENZ Therapeutics (LENZ), Context Therapeutics (CNTX), Verastem Oncology (VSTM), and Veracyte (VCYT).